Xvivo Perfusion AB (LTS:0RKL)
kr 483.29903 12.16762 (2.58%) Market Cap: 15.40 Bil Enterprise Value: 14.98 Bil PE Ratio: 73.15 PB Ratio: 7.28 GF Score: 89/100

Q1 2022 Xvivo Perfusion AB Earnings Call Transcript

Apr 25, 2022 / 12:00PM GMT
Release Date Price: kr238.5 (-3.83%)
Operator

Ladies and gentlemen, welcome to the XVIVO Group Interim Report Q1 2022. I will now hand over to Dag Andersson, CEO. Sir, please go ahead.

Dag Andersson;publ;President;CEO
Xvivo Perfusion AB

()-&

Thank you very much, and good morning, good afternoon or good evening, depending on where in the world you are. So Kristoffer Nordstrom, CFO; and myself, we are very happy to be here in Gothenburg and present the Q1 report to you all. So let's start, let's kick off by talking a little bit about Q1 highlights, and there are quite a few highlights actually to note.

If we look at organic growth, we achieved a great organic growth in the quarter, 32%, and we also delivered an adjusted EBITDA margin of 17%. Worth noting as well, and this was actually already communicated in the last call. During last quarter of 2021 and in connection with the acquisition of STAR Teams, we established the third business area of services. So we have the 3 business areas: Thoracic, Abdominal and now also then Services.

If

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot